Skip to content

Advertisement

  • Original investigation
  • Open Access

Abdominal obesity exhibits distinct effect on inflammatory and anti-inflammatory proteins in apparently healthy Japanese men

  • 1,
  • 1,
  • 1 and
  • 1Email author
Cardiovascular Diabetology20076:27

https://doi.org/10.1186/1475-2840-6-27

©  Nishida et al; licensee BioMed Central Ltd. 2007

  • Received: 24 July 2007
  • Accepted: 01 October 2007
  • Published:

Abstract

Background

Since visceral fat tissue is known to release various inflammatory and anti-inflammatory cytokines, abdominal obesity may play a key role in the inflammation associated with metabolic syndrome (MetS). However, few studies have determined precise relationships of abdominal obesity with inflammatory markers in MetS. To clarify the importance of abdominal obesity in sub-clinical inflammation, we examined the changes of inflammatory markers in clustering of MetS components with or without abdominal obesity.

Methods

Subjects consisted of 326 apparently healthy Japanese men (age: 30 to 59 years) who underwent health examination in the Osaka University Health Care Center. MetS components were assessed and serum levels of high sensitive C-reactive protein (hs-CRP), interleukin (IL)-6 and adiponectin were examined in all subjects.

Results

Subjects with abdominal obesity (waist circumference ≥ 85 cm) showed higher serum hs-CRP and IL-6 levels and a lower adiponectin level than those without abdominal obesity. Serum levels of hs-CRP and IL-6 significantly increased in association with clustering of MetS components in the subjects with abdominal obesity, but not in those without abdominal obesity. On the other hand, serum adiponectin level exhibited a little change with clustering of MetS components in the subjects with abdominal obesity. Significant negative correlation between adiponectin and hs-CRP was observed in the subjects with abdominal obesity, however this correlation was not detected in obese subjects defined by body mass index ≥ 25.

Conclusion

Inflammatory status is not exaggerated by clustering of MetS components in the subjects without abdominal obesity. Abdominal obesity may exhibit distinct effect on inflammatory and anti-inflammatory proteins and modulate inflammatory network in MetS.

Keywords

  • Waist Circumference
  • Abdominal Obesity
  • MetS Component
  • Obesity Group
  • International Diabetes Federation

Background

National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP) III, and American Heart Association (AHA)/National Heart Lung and Blood Institute (NHLBI) proposed definitions of the metabolic syndrome (MetS) as a cluster of at least 3 of 5 following risk factors, abdominal obesity, raised blood pressure, hyper-triglyceridemia, hypo-HDL-cholesterolemia, and raised fasting blood glucose [1, 2]. The primary mechanism for clustering of metabolic abnormalities has yet to be elucidated, but insulin resistance or accumulation of visceral fat is believed as an encouraging candidate [3, 4]. As for visceral fat, the International Diabetes Federation (IDF) newly recommended a definition in which abdominal obesity is the essential component of MetS [5, 6].

Recent studies have proposed an association between MetS and inflammatory markers [7–10]. Abdominal obesity, especially a visceral fat, may play a key role in these situations, because adipose tissue is known to secrete many bioactive substances, including inflammatory and anti-inflammatory proteins [11, 12]. However, only few studies have precisely examined the significance of abdominal obesity in the inflammatory changes observed in MetS [13, 14].

In the present study, we examined inflammatory and anti-inflammatory proteins in Japanese middle-aged men, and investigated whether presence of abdominal obesity has an impact on the inflammatory responses. We here describe unique associations among abdominal obesity, clustering of MetS components, and inflammatory and anti-inflammatory markers.

Methods

Study population

A total of 326 apparently healthy Japanese men, 30 to 59 years of age, who underwent health examination in the Osaka University Health Care Center, were evaluated with MetS components. Individuals with a history of acute illness within 2 weeks or who had taken any medicine were excluded (n = 31) in order to avoid effects on serum levels of inflammatory proteins. Same numbers of subjects with or without abdominal obesity were consecutively selected. Comparison was performed between an "abdominal obesity group" who met the criterion of waist circumference for abdominal obesity and a "non-abdominal obesity group" who did not meet this criterion. Informed consent was obtained from all subjects prior to participation in the study following approval of the study by the Ethics Committee of Osaka University.

Risk factor assessment

Waist circumference at the umbilical level was measured in the late exhalation phase in standing position. Abdominal obesity was diagnosed by waist circumference ≥ 85 cm using the guidelines for abdominal obesity in Japanese individuals [15]. To examine the significant role of abdominal obesity, we employed the definition by IDF [5]. In the criteria of IDF, abdominal obesity is a prerequisite risk factor, and MetS was defined by the existence of abdominal obesity and at least 2 of 4 MetS components defined as follows: 1) hypertriglyceridemia: a serum level of triglycerides (TG) ≥150 mg/dl; 2) low HDL cholesterolemia: a serum level of HDL cholesterol (HDL-C) < 40 mg/dl; 3) hypertension: systolic blood pressure (SBP) ≥ 130 mmHg, or diastolic blood pressure (DBP) ≥ 85 mmHg; 4) high fasting glucose: plasma level of glucose (FPG) ≥100 mg/dl.

Laboratory measurements

Serum was collected from subjects after an overnight fast and kept at ≤ -20°C until assay. Serum immunoreactive insulin was measured by a standard radioimmunoassay method (Dinabott Co., Tokyo, Japan). Homeostasis model assessment of insulin resistance (HOMA-IR) was defined as the product of fasting plasma insulin (μU/ml) and glucose (mg/dl) divided by 405 [16]. Low density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula. However, LDL-C was not calculated if the TG level was >300 mg/dl. Serum high sensitive-C reactive protein (hs-CRP) level was measured with an immunoenzymeassay (Dase Behring, Marburg, Germany). Serum interleukin (IL)-6 concentration was measured in duplicate with a chemiluminescent enzyme immunoassay (CLEIA) (Fujirebio Inc., Tokyo, Japan), and adiponectin was measured duplicate by a sandwich enzyme-linked immunosorbent assay (ELISA) system by adiponectin ELISA kit (Otsuka Pharmaceutical Co., Tokushima, Japan) [17, 18].

Before conducting present study, interclass CVs of hs-CRP, IL-6, and adiponectin measurements were examined (n = 40). Mean CVs of hs-CRP, IL-6, and adiponectin measurements in our assays were 1.1%, 4.5%, and 1.2%, respectively. The same lots of these kits were used in the study to keep reliability of the measurements.

Statistical analysis

All values are mean ± SD. Pearson's correlation coefficients were calculated among skewed variables after logarithmic transformation of variables. ANOVA with Bonferroni post hoc test was used to assess difference between groups. Values of P < 0.05 were considered statistically significant.

Results

Profiles of the study subjects are shown in Table 1. Traditional risk factors were exacerbated and HOMA-IR was increased in abdominal obesity group as compared with non-abdominal obesity group. Abdominal obesity group presented significantly higher hs-CRP and IL-6 levels, and a lower adiponectin level than non-abdominal obesity group.
Table 1

Characteristics of the study subjects

 

All Subjects

Non-abdominal obesity group

Abdominal obesity group

P

n

326

163

163

 

Age, y

45.1 ± 8.1

45.3 ± 8.4

44.8 ± 7.7

n.s.

Waist, cm

84.8 ± 8.2

78.3 ± 4.7

91.2 ± 5.2

<0.0001

BMI, kg/m2

24.3 ± 3.3

22.1 ± 2.0

26.6 ± 2.8

<0.0001

SBP, mmHg

123 ± 16

120 ± 14

127 ± 17

<0.0001

DBP, mmHg

79 ± 12

76 ± 11

82 ± 13

<0.0001

TC, mg/dl

208 ± 35

203 ± 33

214 ± 37

0.003

TG, mg/dl

131 ± 128

100 ± 53

162 ± 168

<0.0001

HDL-C, mg/dl

58 ± 14

62 ± 15

53 ± 11

<0.0001

LDL-C, mg/dl

125 ± 34

120 ± 31

129 ± 37

0.03

FPG, mg/dl

91 ± 10

89 ± 9

93 ± 10

0.0009

HOMA-IR

1.35 ± 2.03

0.75 ± 0.29

1.87 ± 2.67

0.03

hs-CRP, mg/L

0.68 ± 0.77

0.58 ± 0.82

0.78 ± 0.71

0.018

IL-6, pg/ml

1.26 ± 0.75

1.18 ± 0.66

1.34 ± 0.83

0.045

Adiponectin, μg/ml

6.3 ± 2.9

7.1 ± 3.3

5.5 ± 2.1

< 0.0001

Data are mean ± SD. Abdominal obesity and non-abdominal obesity groups are the subjects who met or did not meet the waist criteria (≥ 85 cm). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglycerides; HDL-C: HDL cholesterol; LDL-C: LDL cholesterol; FPG: fasting plasma glucose; HOMA-IR: homeostasis model assessment of insulin resistance; hs-CRP: high sensitive C reactive protein; IL-6: interleukin-6. Statistical significance was examined between non-abdominal obesity and abdominal obesity groups.

The effects of clustering MetS components on inflammatory status were compared between these two groups. Interestingly, in non-abdominal obesity group, serum levels of hs-CRP and IL-6 changed a little in association with clustering of MetS components (Figure 1A). However, serum levels of hs-CRP and IL-6 significantly increased in association with clustering of MetS components in abdominal obesity group (Figure 1B). On the other hand, serum adiponectin level exhibited a little change with clustering of MetS components in abdominal obesity group (Figure 1B), while it was significantly decreased in non-abdominal obesity group. These findings suggest that abdominal obesity may be a key factor in modulating the inflammatory reactions observed in MetS.
Figure 1
Figure 1

Serum levels of hs-CRP, IL-6, and adiponectin. A. Serum levels of hs-CRP, IL-6, and adiponectin in non-abdominal obesity group. Open, hatched, and closed columns represent the subjects with no, one, and two or more metabolic syndrome components except for waist criteria, respectively. Numbers of subjects in open, hatched, and closed columns were 95, 50, and 18, respectively. B. Serum levels of hs-CRP, IL-6, and adiponectin in abdominal obesity group. Columns represent same as described in A. Numbers of subjects in open, hatched, and closed columns were 57, 57, and 49, respectively. Data are mean ± SD. *p < 0.05, **p < 0.01 vs. no metabolic syndrome component (open columns). hs-CRP: high sensitive C-reactive protein; IL-6: interleukin-6; MetS: metabolic syndrome.

We next examined whether these changes of inflammatory markers associate with traditional risk factors. The mean value of risk factor in the subjects either with low or high level of inflammatory marker was compared. Significance of difference was summarized in Table 2. The mean values of waist, TG, and HDL-C showed significant changes associated with classification of adiponectin and hs-CRP levels. FPG was significantly changed between subjects with high and low adiponectin levels. SBP, and DBP levels were significantly changed between subjects with high and low hs-CRP levels. Moreover, stepwise regression analysis revealed waist circumference was a significant determinant for the levels of adiponectin, IL-6, and hs-CRP (Standard regression co-efficient: -0.237, 0.115, and 0.256; F value: 18.6, 4.1, and 20.9; respectively)
Table 2

Difference in mean values of risk factors between the subjects with "High" and "Low" inflammatory markers

 

"High" and "Low" Groups

 

Adiponectin

IL-6

hs-CRP

Waist

<0.0001

0.18

<0.0001

SBP

0.66

0.069

0.0003

DBP

0.21

0.40

0.002

LDL-C

0.82

0.21

0.20

TG

0.0031

0.10

0.0078

HDL-C

<0.0001

0.098

<0.0001

FPG

0.019

0.91

0.46

HbA1c

0.19

0.62

0.50

HOMA-IR

0.11

0.30

0.076

Groups of "High" and "Low" inflammatory markers were divided by the half number of the subjects. Abbreviations are same as described in Table 1. Bold values indicate p < 0.05.

Networks of inflammatory and anti-inflammatory proteins may be altered by the presence of abdominal obesity. Therefore, we next examined the correlation of these markers both in the subjects with abdominal obesity and in obese subjects defined by body mass index (BMI) ≥ 25. As shown in Table 3, correlation was not observed between serum adiponectin and hs-CRP levels in obese subjects (BMI ≥ 25), and even in those with two or more MetS components. However, there was a significant negative correlation between serum adiponectin and hs-CRP levels in abdominal obesity group (r = -0.23 [95%CI, -0.37 to -0.08]). In addition, significant correlation was detected in the subjects with abdominal obesity with two or more MetS components, i.e. MetS (r = -0.29 [95%CI, -0.53 to -0.01]). No significant correlation was observed between adiponectin and IL-6 in both obese and abdominal obese subjects (data not shown).
Table 3

Correlation between serum adiponectin and hs-CRP levels in obesity and abdominal obesity groups

Group

n

Correlation coefficients

95% CI

P

Obesity (BMI ≥ 25)

129

-0.05

-0.22 to 0.13

0.61

with ≥ 2 MetS components

42

-0.12

-0.41 to 0.19

0.44

Abdominal obesity (Waist ≥ 85)

163

-0.23

-0.37 to -0.08

0.003

with ≥ 2 MetS components

49

-0.29

-0.53 to -0.01

0.045

Obesity group includes the subjects with body mass index (BMI) ≥ 25. Abdominal obesity group includes the subjects with waist circumference ≥ 85 cm. MetS: metabolic syndrome. Significant negative correlation between adiponectin and hs-CRP was detected only in the abdominal obesity group. Bold values indicate p < 0.05.

Discussion

It is considered that clustering of metabolic abnormalities presents synergistic effects on cardiovascular complications beyond the sum of effects of individual abnormalities [19]. Therefore, to elucidate the mechanism in clustering of metabolic abnormalities is an important issue. In the present study, percentage of the subjects with two or more MetS components was markedly higher in the abdominal obesity group (30.1%) than the non-abdominal obesity group (11.0%) (data not shown). Abdominal obesity, therefore, might play a pivotal role among various MetS components in the practical definition of MetS. When abdominal obesity was absent, inflammatory proteins, such as hs-CRP and IL-6, did not increase significantly with clustering of MetS components (Figure 1A), despite the fact that previous studies found an association between CRP and MetS [7, 20]. Our results clearly demonstrated association between hs-CRP/IL-6 levels and clustering of MetS components predominantly in the presence of abdominal obesity. Although BMI might also alter inflammatory status, classification by BMI did not present clear association between inflammation and clustering of MetS components (data not shown).

Inflammation may be an important underlying etiology of MetS [8] through its various effects mediated by adipose tissue-derived factors, such as leptin, adiponectin, IL-6, IL-10 and etc. [12]. Many studies demonstrated associations between inflammatory proteins and MetS, abdominal obesity, or insulin resistance. Our results also demonstrate the importance of waist circumference in the changes of inflammatory markers (Table 2). However, abdominal obesity has usually been evaluated as one of the components of MetS. In the present study, we clearly showed that abdominal obesity exhibits distinct association with inflammatory and anti-inflammatory proteins in clustering of MetS components in apparently healthy subjects.

Adiponectin, an anti-inflammatory protein [21], has been demonstrated to be insulin-sensitizing and anti-atherogenic factor, and is considered a key component of MetS [11, 22, 23]. Serum adiponectin level was significantly lower in the subjects with abdominal obesity than those without it, and a marked decrease was observed with clustering of MetS components only in the subjects without abdominal obesity. In agreement with previous reports, low level of serum adiponectin is a potent risk for MetS, and elevation of serum hs-CRP and IL-6 concentration enhances the incidence of MetS in the subjects with abdominal obesity.

Previously, an inverse correlation between expression levels of CRP and adiponectin in adipose tissue from the patients with coronary artery disease had been demonstrated [24]. In the present study, a significant negative correlation was observed between serum adiponectin and hs-CRP levels in the subjects with abdominal obesity, but not in obese subjects. These results suggest that abdominal obesity may exhibit distinct effect on inflammatory and anti-inflammatory proteins. Recently, it is reported that portal concentration of IL-6 is higher than peripheral concentration of it, and visceral fat is identified as an important site for IL-6 secretion [25]. Thus, portal IL-6 from visceral fat might directly induce the production of CRP in the liver. In addition, macrophages infiltrating into visceral fat is another possibility for inflammatory networks specific to the abdominal obesity. It has been reported that macrophage is a source of adipose tissue-derived proteins [26]. The increased number of macrophages infiltrating the visceral fat tissue in individuals with abdominal obesity suggests that adipose tissue itself is a source and site of inflammation [27]. Thus, the inflammatory networks associated with abdominal obesity were distinct from those associated with mere "obesity". Després and Lemienx proposed visceral fat as a dysfunctional adipose tissue [4], and our results support this idea.

In conclusion, without abdominal obesity, inflammatory status is not exaggerated by clustering of MetS components in apparently healthy middle-aged men. Abdominal obesity may exhibit distinct effect on inflammatory and anti-inflammatory proteins and modulates inflammatory network in MetS.

Declarations

Acknowledgements

This work was supported by grants from the Kurozumi Medical Foundation, Tanita Healthy Weight Community Trust, The Japan Health Foundation, and Grant-in-Aid for Scientific Research of Japan Society for the Promotion of Science and for Exploratory Research from Ministry of Education, Culture, Sports, Science and Technology, Japan. The authors gratefully acknowledge Drs. Kazuyuki Yoshizaki and Seiji Takashima who participated in the health examination.

Authors’ Affiliations

(1)
Health Care Center, Osaka University, Machikaneyama, Toyonaka Osaka, 560-0043, Japan

References

  1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.View ArticleGoogle Scholar
  2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.View ArticlePubMedGoogle Scholar
  3. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004, 53: 2087-2094. 10.2337/diabetes.53.8.2087.View ArticlePubMedGoogle Scholar
  4. Deprés JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature. 2006, 444: 881-887. 10.1038/nature05488.View ArticleGoogle Scholar
  5. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome – a new worldwide definition. Lancet. 2005, 366: 1059-1062. 10.1016/S0140-6736(05)67402-8.View ArticlePubMedGoogle Scholar
  6. Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005, 28: 2745-2749. 10.2337/diacare.28.11.2745.View ArticlePubMedGoogle Scholar
  7. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000, 23: 1835-1839. 10.2337/diacare.23.12.1835.View ArticlePubMedGoogle Scholar
  8. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005, 111: 1448-1454. 10.1161/01.CIR.0000158483.13093.9D.View ArticlePubMedGoogle Scholar
  9. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, Sugiura K, Kondo T, Murohara T, Toyoshima H: Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol. 2006, 26: 871-876. 10.1161/01.ATV.0000208363.85388.8f.View ArticlePubMedGoogle Scholar
  10. Nishida M, Moriyama T, Yoshiro Sugita Y, Keiko Yamauchi-Takihara K: Interleukin-10 associates with adiponectin predominantly in subjects with metabolic syndrome. Circ J. 2007, 71: 1234-1238. 10.1253/circj.71.1234.View ArticlePubMedGoogle Scholar
  11. Matsuzawa Y: Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006, 3: 35-42. 10.1038/ncpcardio0380.View ArticlePubMedGoogle Scholar
  12. Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005, 96: 939-949. 10.1161/01.RES.0000163635.62927.34.View ArticlePubMedGoogle Scholar
  13. You T, Ryan AS, Nicklas BJ: The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation. J Clin Endocrinol Metab. 2004, 89: 5517-5522. 10.1210/jc.2004-0480.View ArticlePubMedGoogle Scholar
  14. Forouhi NG, Sattar N, McKeigue PM: Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001, 25: 1327-1331. 10.1038/sj.ijo.0801723.View ArticlePubMedGoogle Scholar
  15. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: New criteria for 'obesity disease' in Japan. Circ J. 2002, 66: 987-992. 10.1253/circj.66.987.View ArticleGoogle Scholar
  16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.View ArticlePubMedGoogle Scholar
  17. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K: Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000, 95: 56-61.PubMedGoogle Scholar
  18. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999, 257: 79-83. 10.1006/bbrc.1999.0255.View ArticlePubMedGoogle Scholar
  19. Muredach PR, Daniel JR: The metabolic syndrome: more than the sum of its parts?. Circulation. 2003, 108: 1546-1551. 10.1161/01.CIR.0000088846.10655.E0.View ArticleGoogle Scholar
  20. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H: The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003, 27: 443-449. 10.1038/sj.ijo.0802260.View ArticlePubMedGoogle Scholar
  21. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000, 102: 1296-1301.View ArticlePubMedGoogle Scholar
  22. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T: Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004, 68: 975-981. 10.1253/circj.68.975.View ArticlePubMedGoogle Scholar
  23. Nishida M, Funahashi T, Shimomura I: Pathophysiological significance of adiponectin. Med Mol Morphol. 2007, 40: 55-67. 10.1007/s00795-007-0366-7.View ArticlePubMedGoogle Scholar
  24. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003, 107: 671-674. 10.1161/01.CIR.0000055188.83694.B3.View ArticlePubMedGoogle Scholar
  25. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007, 56: 1010-1013. 10.2337/db06-1656.View ArticlePubMedGoogle Scholar
  26. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112: 1796-1808. 10.1172/JCI200319246.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Bruun JM, Lihn AS, Pedersen SB, Richelsen B: Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab. 2005, 90: 2282-2289. 10.1210/jc.2004-1696.View ArticlePubMedGoogle Scholar

Copyright

© Nishida et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Cardiovascular Diabetology

ISSN: 1475-2840